Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2000-07-07
2003-09-30
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C536S023500, C530S350000, C435S252300, C435S254100, C435S069100, C424S178100, C424S001730
Reexamination Certificate
active
06627199
ABSTRACT:
FIELD OF THE INVENTION
The invention is in the field of recombinant genetics. In particular, the present invention relates to a novel transmembrane decoy-receptor, tmst2, and its secreted splice variant, belonging to the TNF-receptor super genie family and nucleic acid molecules encoding same. The invention also relates to vectors, host cells, antibodies and recombinant methods for producing both the membrane associated and the soluble forms of the receptor polypeptides. The invention also relates to the use of the recombinant tmst2 receptor polypeptide to identify putative binding proteins. In addition, methods and reagents are provided for the diagnosis of diseases associated with or resulting from abnormal tmst2 and/or abnormal expression of its putative ligand, and methods and pharmaceutical composition(s) for the treatment, amelioration and/or treatment of diseases associated with abnormal tmst2 or abnormal expression of tmst2 and/or its ligand. The invention also discloses pharmaceutical compositions for use in the treatment of these diseases.
BACKGROUND OF THE INVENTION
Technical advances in the identification, cloning, expression and manipulation of nucleic acid molecules have greatly accelerated the discovery of novel therapeutics based upon deciphering the human genome. Rapid nucleic acid sequencing techniques can now generate sequence information at unprecedented rates, and coupled with computational analyses, allow the assembly of overlapping sequences into the entire genome and the identification of polypeptide-encoding regions. Comparison of a predicted amino acid sequence against a database compilation of known amino acid sequences can allow one to determine the extent of homology to previously identified sequences and/or structure landmarks. Cloning and expression of a polypeptide-encoding region of a nucleic acid molecule provides a polypeptide product for structural and functional analysis. Manipulation of a nucleic acid molecule(s) and encoded polypeptide(s) to give variants and derivatives thereof may confer advantageous properties on a product for use as a therapeutic.
However, in spite of the significant technical advances in genome research over the past decade, the potential for development of novel therapeutics based on the human genome is still largely unrealized. While a number of genes encoding potentially beneficial protein therapeutics, or those encoding polypeptides which may act as “targets” for therapeutic molecules, have been identified using recombinant DNA technology, the structure and function of a vast number of genes in the genome of mammals are yet unknown.
Using the above mentioned recombinant DNA technology, we have recently identified a new member of the tumor necrosis factor (TNF)-receptor supergene family, hereinafter referred to as “tmst2”, and secreted splice variant of tmst2-receptor polypeptide, hereinafter referred to as tmst2 which may elicit its effects by binding a member of the TNF-family of ligands.
Identification and Characterization of TNF-Family of Ligands and Receptors
Tumor necrosis factor (TNF) was first identified in the serum of mice and rabbits which had been infected with bacillus of Calmette and Guerin(BCG) and which had been injected with endotoxin. TNF activity in the serum of these animals was recognized on the basis of its cytotoxic and anti-tumor activities. This TNF activity, referred to as TNF-&agr;, is produced particularly by activated monocytes and macrophages, and has been implicated in normal growth processes as well as in a variety of diseases.
Following the discovery of TNF-&agr;, independent research led to the identification of another cytokine associated with inflammatory responses lymphotoxin-&agr; (LT-&agr;) which was shown to be produced exclusively by lymphocytes. LT-&agr; was subsequently shown to be 30% homologous with TNF-&agr;, and was renamed TNF-&bgr;. It is now clear that TNF-&agr; and TNF-&bgr; are members of a gene family that includes yet another member termed LT-&bgr; (Browning et al.,
Cell
72:847-856 (1993)). The three genes are tightly linked within the MHC complex and show similar organization. Moreover, the biologically active forms of TNF-&agr; and TNF-&bgr; are homotrimers and share many of the same biological activities including competing for the same cell-surface receptors (Agarwal et al.,
Nature
318:665-667 (1985)). Two distinct but structurally homologous receptors have been identified, and each has been shown to bind both the ligands and mediate their effects.
However, it has been recognized that TNFs are only representative members of the rapidly expanding supergene family that includes TNF-&agr;, TNF-&bgr;/lymphotoxin-&agr; (LT-&agr;), lynphotoxin-&bgr; (LT-&bgr;), FasL, CD40L, CD30L, CD27L, 4-IBBL, and TNF-related apoptosis-inducing ligand (TRAIL), RANKL, GITRL and TNF-2. The distinctive but overlapping cellular responses induced by members of the TNF family of ligands following their interaction(s) with their cognate cell-surface receptors result in clearly defined developmental and regulatory changes in cells of the lymphoid, hematopoietic, and other lineages. For example, TNF family of ligands are involved in growth regulation and differentiation of cells which are involved in inflammation, immune processes and hematopoiesis (Bayert, R. and Fiers, W.,
Tumor Necrosis Factor and Lymphokines
in: Cytokines eds. Anthony Mire-Sluis and Robin Thorpe, Academic Press San Diego Calif. (1998)). TNF family of ligands activate the immune defenses against parasites, and acts directly and/or indirectly as a mediator in immune reactions and inflammatory processes. However, administration of TNF and/or other members of the TNF family can also be accompanied by harmful phenomena such as shock and tissue damage (Bayert, R. and Fiers, W., supra). The main physiological role of TNF family of ligands is likely the activation of first-line reaction of an organism to microbial, parasitic, viral, or to mechanical stress and cancer. For example, TNF-related apoptosis-inducing ligand (TRAIL) has been demonstrated to induce apoptosis of a number of different types of cancer cells as well as virally infected cells.
Furthermore, a number of observations have also led to the conclusion that TNF family of ligands are also involved in a variety of pathological conditions including cachexia, toxic shock syndrome, inflammatory diseases such as rheumatoid and osteoarthritis, in death resulting from graft-versus- host reaction (GVHR)(Bayert, R. and Fiers, W., supra), rapid necrosis of tumors, apoptosis, immunostimulation and resistance to parasites and viruses.
Like other cytokines, the TNF family of ligands binds to specific cell surface receptors. Based upon sequence similarities, the TNF receptors belong to a receptor gene super-family that includes the low-affinity nerve growth factor (NGF) receptor, the FAS antigen, the human B-lynphocyte activation molecule CD40, CD27, 4-1BB, PV-T2, CD30, TNF R-RP, TRAIL-R, PV-A53R, RANK, GITR and OX40 antigen found on activated T cells (Smith et al.,
Cell
, 76: 959-62 (1994): Baker and Reddy,
Oncogene
, 12: 1-9 (1996)). Sequence similarities between any two family members may exist throughout the molecule, or be confined to the extracellular or intracellular domain. The intracellular domain of some of the receptors contains a so-called death domain (DD), which mediates ligand-induced programmed cell death (apoptosis). The pathways employed to induce death differ among death domains of individual TNF receptors. For example, the FAS antigen DD signals through FADD, RIP and caspase-8; the TNFR-1 signals through FADD, TRADD and caspase-8; and the death domain of the TRAIL-receptor DR4 induces apoptosis without interacting with any of the above adapter molecules. The sequence diversity among extracellular domains of the TNF receptor family is reflected in their binding specificities: some bind TNF, others do not.
In addition to the membrane associated receptor molecules described above, a number the receptors belonging to the TNF-receptor supergene family
Amgen Inc
Marshall Gerstein & Borun
O'Hara Eileen B.
Spector Lorraine
LandOfFree
Isolation, identification and characterization of tmst2, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolation, identification and characterization of tmst2, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolation, identification and characterization of tmst2, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3101096